Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NM8074 in Atypical Hemolytic Uremic Syndrome (aHUS)
NCT05684159Phase 2Not yet recruiting
- Sponsor
- NovelMed Therapeutics
- Start
- Nov 2027
- Primary completion
- Apr 2030
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of ruxoprubart in atypical hemolytic uremic syndrome (aHUS), sponsored by NovelMed Therapeutics. Planned start Nov 2027; status: not yet recruiting.
02
Drugs
ruxoprubart
03
Conditions
atypical hemolytic uremic syndrome (aHUS)
Beyond the preview
Go deeper on NCT05684159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05684159.